FindTrial
Sign In

Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis:a prospective randomized controlled trial

Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis:a prospective randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069036
Enrollment
Unknown
Registered
2023-03-05
Start date
2023-03-05
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

ILIT group:intralymphatic immunotherapy
SCIT group:subcutaneous immunotherapy

Sponsors

The Third affiliated Hospital of SunYat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: aged 18-50 years old, serum sIgE or skin prick test positive for house dust mites/dust mites, and no more than 2 allergen positive types; Routine drug treatment can not effectively control symptoms; Patients are unwilling to accept continuous or long-term drug treatment; Patients understand the risks and effects of immunotherapy.

Exclusion criteria

Exclusion criteria: patients with asthma; Patients with cardiovascular and other systemic chronic diseases; Patients with malignant tumors; Unable to understand the risk and efficacy of immunotherapy, patients with mental illness; Pregnant women and children.

Design outcomes

Primary

MeasureTime frame
CMI;—

Secondary

MeasureTime frame
RQLQ;sIgE/tIgE;patient-reported outcomes;—

Countries

China

Contacts

Public ContactHuang xuekun

The Third affiliated Hospital of SunYat-sen University

xuekunhuang@163.com13660871873

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026